{
    "clinical_study": {
        "@rank": "16601", 
        "arm_group": {
            "arm_group_label": "BP-C1 IM Injections", 
            "arm_group_type": "Experimental", 
            "description": "BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days."
        }, 
        "brief_summary": {
            "textblock": "This study is an open label, non-randomized phase I single-armed study in women with\n      metastatic breast cancer (MBC). The purpose of the study is to estimate the pharmacokinetic\n      (PK), tumor necrosis factor-\u03b1(TNF-\u03b1) and interleukin-\u03b2(IL-\u03b2), Interferons, IL-1\u03b2, IL-2,\n      IL-4, IL-6, IL-8, IL-10, IL-12, IL-21 and IL-25 levels and pattern after single and multiple\n      BP-C1 injections. Additionally to perform a pharmacodynamic (PD) analysis by PK-PD modelling\n      with interleukins and change in tumour size."
        }, 
        "brief_title": "BP-C1 in Metastatic Breast Cancer Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "All six MBC patients will be recruited from the single participating site. Each included\n      patient will participate in a screening period of maximum 21 days + 32 days treatment period\n      + 28 days follow-up period. If no further treatment is indicated beyond 32 days as per the\n      principal investigator, the maximum duration for one patient will then be 81 days.\n\n      The patients will be treated continuously in 32 days with one intramuscular (IM) injection\n      of 0.035 mg/kg bodyweight (0.07 ml/Kg) of BP-C1 daily. This represents a cumulative dose of\n      1.12 mg/kg bodyweight (2.24 ml/kg)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female MBC patients classified as stage IV\n\n          -  18 and 80 years of age\n\n          -  Measurable lesions / lymph node\n\n          -  Have previously undergone all available standard chemotherapy\n\n          -  Expected survival time exceeding 3 months\n\n        Exclusion Criteria:\n\n          -  Known breast cancer susceptibility gene(BRCA) 1/2 positive tumor suppressor gene\n             mutation\n\n          -  Abnormal liver function classified as total Bilirubin >34 micromol/l or alanine\n             aminotransferase(ALAT) > 3 times the upper limit of normal range (ULN). In case of\n             metastases in the liver, the ALAT limit for exclusion is set to 5 x ULN.\n\n          -  Abnormal kidney function defined by serum creatinine >120 micromol/l.\n\n          -  Abnormal coagulation capacity defined by the relative arbitrary concentration of\n             coagulation factors 2,7,10 international normalized ratio(INR) >1.3\n\n          -  Patients with verified metastasis to the brain\n\n          -  Synchronous cancer except for non-melanoma skin cancer and early stage of cervical\n             cancer\n\n          -  Abnormal haematology status defined by Hgb < 9.0 gr/dl, platelet count < 100.000/mm3\n             and leucocytes < 3 x 109/l\n\n          -  Clinical significant abnormal ECG\n\n          -  Karnofsky score <60%\n\n          -  Pregnant or breast feeding women\n\n          -  Women of fertile age who do not want to be tested for possible pregnancy.\n\n          -  Fertile female who do not want to use safe protection against pregnancy, starting one\n             month before start of the trial treatment and lasting at least six weeks after.\n\n          -  Uncontrolled bacterial, viral, fungal or parasite infection.\n\n          -  Under systemic treatment with corticosteroids or other immunosuppressive drugs during\n             the last 21 days before start of the trial treatment.\n\n          -  Participating in another clinical trial with pharmaceuticals during the last six\n             weeks before start of this trial treatment.\n\n          -  Not able to understand written or oral information\n\n          -  Do not want or is not able to give written consent to participate in the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861509", 
            "org_study_id": "BMC 2012-4", 
            "secondary_id": "2011-006316-31"
        }, 
        "intervention": {
            "arm_group_label": "BP-C1 IM Injections", 
            "intervention_name": "BP-C1", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ramat-Gan", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "Oncology Unit. Sheba Medical Centre"
            }, 
            "investigator": {
                "last_name": "Shani Paluch-Shimon, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer: A Phase I(D) Study", 
        "overall_contact": {
            "email": "slj@meabco.com", 
            "last_name": "Steen Lindk\u00e6r-Jensen, Prof.", 
            "phone": "+45 32 46 03 70"
        }, 
        "overall_contact_backup": {
            "email": "Stig.Larsen@nvh.no", 
            "last_name": "Stig Larsen, Prof."
        }, 
        "overall_official": {
            "affiliation": "Sheba Medical Centre, Ramat-Gan, Israel.", 
            "last_name": "Shani Paluch-Shimon, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Day 1, Day 8, Day 16, Day 24, Day 32"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day-1, Day 1, Day 16, Day 32 and Day 34"
            }, 
            {
                "measure": "Time required for half the quantity of the BP-C1 to be metabolized or eliminated by normal biological processes", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Day 1, Day 8, Day 16, Day 24, Day 32"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC(0-t))", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Day 1, Day 8, Day 16, Day 24, Day 32"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC(0-\u221e))", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Day 1, Day 8, Day 16, Day 24, Day 32"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Interleukin Interferon \u03b3 and \u03b2, Tumour Necrosis Factor (TNF-\u03b1), IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-21 and IL-25", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Day 1, Day 16, Day 32, Day 34"
            }, 
            {
                "measure": "The total changes in size and numbers of metastases", 
                "safety_issue": "No", 
                "time_frame": "following 32 days of treatment and after a FU of 28 days"
            }
        ], 
        "source": "Meabco A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meabco A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}